Close, but you need to do a two-sample test. Wolfram Alpha
Close, but you need to do a two-sample test. Wolfram Alpha has one you can play around with: wolframalpha.com/input/?i=two+binomial+distribution+test
Enter 0 for the "hypothesized parameter" to indicate the null hypothesis that there is no effect of leronlimab. Then enter the mortality data for the control group as sample 1 and leronlimab data for sample 2. There's a link below the data form for toggling between entering the number of fatalities or the proportion and a "Compute" button below that.
A caveat: this test is based on a normal approximation to the binomial, which works well when the number of fatalities in each group is not small (n >= 5 as a rule of thumb) but kind of falls apart when the number of fatalities is small. It most likely is not exactly the same test that they'll use for the analysis, but it will be in the same ballpark for sure (except possibly for the small numbers, where it might be quite a bit different).
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Key Disclosure on Voting Rights and Shares As a reputable leader in stationery and consumer products, BIC is committed to transparency. Recently, they provided crucial insights into their corporate structure, particularly regarding the total number of voting rights and shares. This disclosure highlights the ongoing dedication towards maintaining clear communication with...
Continue Reading
AGCO (NYSE: AGCO) is strutting its stuff at the 2026 Commodity Classic in San Antonio from February 25-27. Picture this: over 24,000 square feet jam-packed with cutting-edge agricultural machinery aimed at farmers who want to boost their operations. Yeah, the buzz is all about showcasing their big guns like Fendt®, Massey Ferguson®, and PTx™—but dig deeper into...
Continue Reading
Revolutionizing Healthcare Marketing with Ignite Pulse Solutions In the shifting landscape of healthcare marketing, WebMD Ignite introduces a significant enhancement aimed at assisting health systems in thriving amidst the challenges posed by AI and budget constraints. Presenting Ignite Pulse™, this groundbreaking solution offers a comprehensive growth strategy designed...
Continue Reading
Eupraxia Pharmaceuticals Expands Leadership Team Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX), known for its innovative approaches in drug delivery technology, has recently announced two significant additions to its leadership. Dr. Amanda Malone has been appointed as the Chief Operating and Scientific Officer, alongside Dr. Rahul Sarugaser as Executive Vice...
Continue Reading
Illumina's Latest Developments in Oncology In an exciting development, Illumina Inc. (NASDAQ: ILMN) has announced a significant expansion in its clinical oncology portfolio. This move aims to set a new standard of care and enhance access to precision therapies through advanced genomic profiling. Following the recent FDA approval of Illumina's TSO Comprehensive test, the...
Continue Reading